Literature DB >> 33062966

Colour Coding Navigation: "Triage" Techniques to Improve Compliance in Breast Cancer Patients Requiring Primary Chemotherapy.

Carol Ann Benn1, Yastira Ramdas1, Barend van den Bergh1, Naa-Lamle Bannerman1, Dominic van Loggerenberg1, Tia van Loggerenberg1, Vernon Shaw1.   

Abstract

OBJECTIVE: This is a pilot study to assess whether a file-colour-coded triage navigation system for patients on primary chemotherapy improves compliance and adherence and if it decreases defaulting.
MATERIALS AND METHODS: All breast cancer patients are discussed in a multidisciplinary meeting. All patients are triaged before starting on primary chemotherapy based on their specific challenges and beliefs and are consulted by the navigation team and contacted before the beginning of treatment and after each chemotherapy session by a navigator in the unit. File stratification for ease of navigation was instituted by a colour code dot into three groups. The three groups are:Code Green: Compliant on treatmentCode Yellow: Side effects on treatment/ considering defaultingCode Red: Non-compliantThe code red patients were further assessed in terms of reasons for non-adherence or non-compliance:Fear of chemotherapy side effectsThe belief that chemotherapy kills the patientInterest in "alternative treatment regimens"Other barriers to treatment as identified by the navigators.
RESULTS: The system allows the navigation team to focus on which patients require specific navigation and inform the treating oncologists. Code green patients were courtesy called after each chemotherapy session. The code yellow patients had early involvement with the survivorship team to ensure appropriate management of any side effects. Access to the complimentary oncology navigator and complementary health website was instituted. The oncology navigator visited each patient at the oncology unit on the day the patient was due to have chemotherapy. For Code red 1 and 2, a "buddies" network of patients who have been through similar treatment regimens was assigned by the navigation team. This was coordinated by patient navigators (trained counsellors who have had breast cancer treatment). Code red three was managed by a complementary health specialist who understood the value of chemotherapy. For Code red 4, the oncology navigator manages the concerns from finances services to family issues. For the 122 patients in total for primary chemotherapy, stratification was as follows:Code Green=64.8%Code Yellow=27.0%Code Red=8.2%.
CONCLUSION: This system provides the Multidisciplinary team with the opportunity to improve patient adherence/compliance with primary chemotherapy. 80% of the code red patients eventually agreed to receive the recommended treatment. Navigation enhanced patient supervision, and the coding system improved patient primary chemotherapy adherence. Such a system would benefit larger oncological practices to improve primary chemotherapy adherence by empowering the navigation team to identify patients requiring more intensive navigation supervision.
Copyright © 2020 Turkish Federation of Breast Diseases Associations.

Entities:  

Keywords:  Breast cancer; navigation; neoadjuvant chemotherapy; patient adherence; patient compliance

Year:  2020        PMID: 33062966      PMCID: PMC7535990          DOI: 10.5152/ejbh.2020.5784

Source DB:  PubMed          Journal:  Eur J Breast Health


  10 in total

Review 1.  Homeopathy in cancer care.

Authors:  Moshe Frenkel
Journal:  Altern Ther Health Med       Date:  2010 May-Jun       Impact factor: 1.305

Review 2.  Patient navigation in breast cancer: a systematic review.

Authors:  Stephanie Robinson-White; Brenna Conroy; Kathleen H Slavish; Margaret Rosenzweig
Journal:  Cancer Nurs       Date:  2010 Mar-Apr       Impact factor: 2.592

3.  Determinants of the use of complementary therapies by patients with cancer.

Authors:  O Paltiel; M Avitzour; T Peretz; N Cherny; L Kaduri; R M Pfeffer; N Wagner; V Soskolne
Journal:  J Clin Oncol       Date:  2001-05-01       Impact factor: 44.544

Review 4.  Update on cancer chemotherapy: general considerations and breast cancer. Part II.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1985-09       Impact factor: 1.798

5.  What's in a name? Compliance, adherence and concordance in chronic psychiatric disorders.

Authors:  Subho Chakrabarti
Journal:  World J Psychiatry       Date:  2014-06-22

6.  Why do some patients prefer to leave decisions up to the doctor: lack of self-efficacy or a matter of trust?

Authors:  Neetu Chawla; Neeraj K Arora
Journal:  J Cancer Surviv       Date:  2013-07-27       Impact factor: 4.442

7.  The preference to receive chemotherapy and cancer-related outcomes in older adults with breast cancer CALGB 49907 (Alliance).

Authors:  Ajeet Gajra; Linda McCall; Hyman B Muss; Harvey J Cohen; Aminah Jatoi; Karla V Ballman; Ann H Partridge; Linda Sutton; Barbara A Parker; Gustav Magrinat; Heidi D Klepin; Jacqueline M Lafky; Arti Hurria
Journal:  J Geriatr Oncol       Date:  2018-03-28       Impact factor: 3.599

8.  Characterizing breast conditions at an open-access breast clinic in South Africa: a model that is more than cancer care for a resource-limited setting.

Authors:  Sarah Rayne; Naomi Lince-Deroche; Cheryl Hendrickson; Kate Shearer; Faith Moyo; Pam Michelow; Grace Rubin; Carol Benn; Cynthia Firnhaber
Journal:  BMC Health Serv Res       Date:  2017-01-21       Impact factor: 2.655

9.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.

Authors:  A Goldhirsch; E P Winer; A S Coates; R D Gelber; M Piccart-Gebhart; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2013-08-04       Impact factor: 32.976

10.  Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.

Authors:  J Ferlay; M Colombet; I Soerjomataram; C Mathers; D M Parkin; M Piñeros; A Znaor; F Bray
Journal:  Int J Cancer       Date:  2018-12-06       Impact factor: 7.396

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.